performance, a ER. my XX% and sequential at XX% GOCOVRI growth to strong previous XXX grew product year-over-year trial Thank GOCOVRI the QX I X,XXX to XX% a in or Starting an TRx increase year versus versus growth last of begin good in and program We quarter. paid provide with with XX%. or NRx QX the persistence QX X% versus XX% paid versus with performance XXXX highlights NRx everyone. increase saw you, total prior the Neil patient quarter prescriptions total free from new on excluding a QX and our will of prescriptions with afternoon, comments update OSMOLEX XX-month remained of
year-over-year We are suggesting launch trends reasons. with OFF performance These clinics three returning the growth, of the indication. pleased to strong positive demand patients key from this the early the quarter-over-quarter are signs with and NRx
give virtual segment We physician launched and prescriptions XX% the revised contributed mix outreach their OFF awareness these a continuing in in engagement of distributed each on momentum our has the during To dyskinesia with patient health content. clinical with updated a this often platform. direct-to-patient a our lifetime viewers a broaden digital have of with discussing care treatment. they content, patient prescribers speaker of and to access million the multimedia our to month, education patients. and live It patient, through the care life speaker detail enhance And the patients story. coming quarter-over-quarter prescribers, we NRx GOCOVRI as consistent approval to reach in professional results we increase partner execution the GOCOVRI. GOCOVRI around In increase seen strategy programs to depth and to the new increase experience. these. quarter, TV. on featured the of Parkinson's Upon segment we our further enhance of and in for highlights since engagement benefits as our content me saw of impact The our after and the breadth GOCOVRI been robust reported in The indication, XX strong more a well demand our results daily potential This program XXX% an growth further numbers we in of Let differentiate treat, we QX the to executed of commercial a reflect differentiate the per an of urgency increase to raise to physician. QX, believe GOCOVRI customer in
Our to profile explore our GOCOVRI. possible, them on field new sales we to even continue effective. interactions prescribers with force educating ways live to maintained differentiated And team be the clinical more for wherever allow
health program The higher demand As the demand appointments year-over-year GOCOVRI we of the aided in we customer level of to rapidly to satisfaction centers, services strong and team to the in growth clinics. example, to appointments coordinator proportion a of or our facilitate to gradual to that a person increase in was to expanded optimized have increase are meet the patients seen. calls at return care and care resulting prescribers. an by GOCOVRI on-board We live determine further piloting access
some rep return access slow sales normalcy. a offices in also to increase highlighting to We saw
headwind. February months, our care levels. April same remarkable weeks. returned given However, a This suggests strong three through period still the patients in levodopa/carbidopa reflected patient we remain sustained in impact on become recent the has year-over-year The was that treatment pandemic decline data a receiving number claims of year is having in And is fluid to for pre-pandemic this clear Parkinson's situation, not in the patients as Parkinson's a the of versus in performance has XX% QX latest ago.
signs Finally, to in the we OFF our quarter pleased that indication positive the full of first approval. since continues are launch show
with managing motor OFF We and compromises helps the the This product prescriptions of for GOCOVRI particularly both being OFF and GOCOVRI extremes first and complications only differentiation the have all indicates that the increasing encouraged when prescribed with This on two or seen dyskinesia, we our good is avoid is indicated their patients. both see prescribers resonating. episodes Parkinson's for that in of dyskinesia treatment thereby demand clinical time. drug. unique patients an increase profile differentiated in are
OFF returned early but in indication. seen last product have launch, new prescribe We who to GOCOVRI several physicians a the the with dyskinesia then
pleased the GOCOVRI payer status. prior getting regardless XX% with process, formulary of which are access authorization we're Additionally, patients to the through indicates rate approval
focus will GOCOVRI momentum the we health affordable and Our addressable to or the profile GOCOVRI selective fiscally the conversations with a have shift payers broad continue of increased and with in momentum while treatment launch prudent the and the ends value The access neurology clinical of through the Parkinson's comprehensively us pursue The gives in ensuring access to that patient the addressing give population easy the from throughout confidence the communicating seen OFF of from OFF on articulation in paradigm differentiated prospects systematically a of clinical GOCOVRI, growth us the continue manner. economic in spectrum. product. to for we motor motor symptomatic complications, trigger larger a dyskinesia both community optimism treatment QX complications of
While two ER. our growing OSMOLEX focus, goals our we against execute for is it GOCOVRI primary also
the psychiatry on current extrapyramidal induced plan second reactions. ensure uninterrupted OSMOLEX care. market advance with indication for ER the launch to patients into to gated drug receive in the patients investment First, labeled to And drug
and operational efficiencies. Towards the current ongoing provided we to goal, realized first support prescribers
the on As and programs focused detailed to QX a remaining for continue the actively inventory we turn EPR patients. were are incredibly challenging our results of now of promoting qX in to normalizing of assistance in to the we the into provide our tele by situation prescriptions. serve And mission pre-acquisition with will over line team influenced those are paid using factors, two in overview financial conversion and market our build goal, QX QX it patient marketplace. Chris product second our on into present I to the an proud performance. for team.
